AEON Biopharma (AEON) Projected to Announce Earnings on Tuesday

AEON Biopharma (NASDAQ:AEON) will likely be issuing its results before the market opens on Tuesday, August 11th. Analysts expect AEON Biopharma to announce earnings of ($0.2250) per share for the quarter.

AEON Biopharma Price Performance

Shares of AEON stock traded up $0.01 on Tuesday, reaching $0.31. 221,292 shares of the stock were exchanged, compared to its average volume of 628,976. AEON Biopharma has a one year low of $0.22 and a one year high of $1.45. The stock has a market cap of $7.74 million, a PE ratio of 1.71 and a beta of 0.61. The stock has a 50 day moving average price of $0.57 and a 200 day moving average price of $0.87.

Analysts Set New Price Targets

AEON has been the topic of several analyst reports. Lake Street Capital started coverage on shares of AEON Biopharma in a report on Thursday, July 30th. They issued a “buy” rating and a $1.00 price objective on the stock. Zacks Research upgraded AEON Biopharma to a “hold” rating in a research report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $1.00.

Institutional Investors Weigh In On AEON Biopharma

A hedge fund recently raised its stake in AEON Biopharma stock. Geode Capital Management LLC increased its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,134 shares of the company’s stock after purchasing an additional 13,061 shares during the period. Geode Capital Management LLC owned approximately 0.51% of AEON Biopharma worth $66,000 at the end of the most recent quarter. Institutional investors and hedge funds own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical?stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.